Academic Journals Database
Disseminating quality controlled scientific knowledge

Second-line Chemotherapy and Its Survival Analysis of 181 Patients with
Extensive-stage Small Cell Lung Cancer in a Single Institute

Author(s): Manjiao MA | Mengzhao WANG | Yan XU | Ke HU | Huihui LIU | Longyun LI | Wei ZHONG | Li ZHANG | Jing ZHAO | Huazhu WANG

Journal: Chinese Journal of Lung Cancer
ISSN 1009-3419

Volume: 16;
Issue: 11;
Start page: 572;
Date: 2013;
Original page

Keywords: Extensive-stage small cell lung cancer | Second-line chemotherapy | Survival | Prognostic factors

Background and objective Small cell lung cancer (SCLC) is the most malignant neuroendocrine tumor and sensitive to chemotherapy and radiotherapy. However, most patients who receive first-line chemotherapy will relapse within one to two years. Once recurrent, it indicates poor prognosis. Currently, the standard first-line chemotherapy regimen of extensive-stage SCLC is platinum combined etoposide regimen while the standard second-line chemotherapy regimen is open to debate. The aim of this study is to analysis the prognostic factors of second-line chemotherapy in extensive-stage SCLC and to compare the differences of objective response rate, side effects and survival among different second-line chemotherapy regimens. Methods 181 patients who were diagnosed as extensive-stage SCLC and received second-line chemotherapy were collected. χ2 test was used to analysis the differences of enumeration data and between different groups. Kaplan-Meier method was used to calculate the overall survival (OS) and progression-free survival (PFS). Univariate analysis and Cox regression analysis were used to detect the prognostic factors. Objective response rate was evaluated by RECIST criteria and side effects were evaluated by WHO criteria. Results The patients who received second-line chemotherapy can be divided into 6 groups, namly group A (CE/EP regimen) 27 cases, group B (regimens containing TPT) 44 cases, group C (regimens containing CPT-11) 33 cases, group D (regimens containing TAX/DXL) 20 cases, group E (regimens containing IFO) 28 cases and group F (other regimens) 29 cases. The median OS in second-line chemotherapy as 7.0 months and was relevant with smoking history (P=0.004), ECOG PS (P
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona